MedPath

Egetis Therapeutics to Explore Tiratricol (Emcitate®) for Resistance to Thyroid Hormone Beta (RTHβ)

• Egetis Therapeutics will investigate tiratricol (Emcitate®) for Resistance to Thyroid Hormone beta (RTHβ), a rare genetic disorder with no approved treatments. • A multicenter, investigator-initiated Phase 2 study in RTHβ patients is being contemplated in collaboration with academia, leveraging tiratricol's Orphan Drug Designations. • RTHβ affects 1-2 individuals per 40,000 live births and results in impaired thyroid hormone signaling, leading to a mix of thyrotoxicosis and hypothyroidism symptoms. • Clinical data indicates RTHβ patients face reduced survival and increased cardiovascular morbidity, highlighting the urgent need for effective therapies.

Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) has announced its decision to explore tiratricol (Emcitate®) as a potential treatment for Resistance to Thyroid Hormone beta (RTHβ). The company is considering supporting a multicenter, investigator-initiated Phase 2 study in collaboration with academic partners.
RTHβ is a rare genetic disorder characterized by impaired thyroid hormone signaling due to mutations in the thyroid hormone receptor beta gene. This condition affects an estimated 1-2 individuals per 40,000 live births and currently has no approved treatments, representing a significant unmet medical need. Thyroid hormone, crucial for tissue development and metabolic regulation, acts through nuclear thyroid hormone receptors, influencing the transcription of hormone-responsive genes. RTHβ disrupts this process, leading to a combination of thyrotoxicosis and hypothyroidism symptoms across different tissues.

Clinical Manifestations and Disease Burden

Clinical manifestations of RTHβ include goiter, hepatic steatosis, dyslipidemia, impaired hearing and color vision, neurocognitive dysfunction, and cardiovascular stress. Recent studies have highlighted the severity of the condition, demonstrating that patients with RTHβ experience reduced survival and increased cardiovascular morbidity. Okosieme et al. (2023) and Campi et al. (2024) have published data underscoring these risks, emphasizing the need for effective therapeutic interventions.

Tiratricol (Emcitate®) and RTHβ

Tiratricol (Emcitate®) has received Orphan Drug Designation for RTHβ in both the USA and EU. This regulatory status underscores the potential of tiratricol to address this rare and serious condition. It is important to note that RTHβ is a distinct indication from MCT8 deficiency, with no overlap in patient populations. Egetis Therapeutics is also developing tiratricol for MCT8 deficiency.

Future Development Plans

Egetis Therapeutics plans to share further details on the specific development plans for tiratricol in RTHβ after finalization. An RTHβ presentation and unmet medical need will be given at Egetis’ Investor Day on December 18, 2024.
Nicklas Westerholm, CEO of Egetis Therapeutics, and Karl Hård, Head of Investor Relations & Business Development, are available for further inquiries regarding this development.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

European Commission Approves Emcitate (Tiratricol) as First Treatment for MCT8 Deficiency

The European Commission has granted marketing authorization for Emcitate (tiratricol), making it the first approved treatment for monocarboxylate transporter 8 (MCT8) deficiency in the EU.
The approval is based on data from Triac Trial I, the Erasmus University Medical Center Cohort Study, and preliminary results from Triac Trial II, demonstrating significant reductions in serum T3 concentrations.

Gene Therapies Show Promise in Targeting the Root Cause of Rett Syndrome

Two companies, Neurogene and Taysha Gene Therapies, are in Phase 1/2 clinical trials with gene therapies targeting the MECP2 gene for Rett syndrome.
These therapies aim to address the underlying genetic cause of Rett syndrome, unlike existing treatments that only manage symptoms.

Vir Biotechnology Receives Positive EU Opinion for Orphan Drug Designation of Tobevibart and Elebsiran in Chronic Hepatitis Delta

The EMA's COMP issued a positive opinion for orphan drug designation of tobevibart and elebsiran for chronic hepatitis delta (CHD).
The decision was based on encouraging preliminary data from the Phase 2 SOLSTICE trial, with 24-week data presented at The Liver Meeting.

EnteroBiotix Completes Phase 2 Trial Recruitment of EBX-102-02 for Irritable Bowel Syndrome

EnteroBiotix has completed recruitment for its Phase 2 TrIuMPH trial, which is evaluating EBX-102-02 in 122 patients with moderate to severe irritable bowel syndrome (IBS).
The trial includes patients with both constipation-predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D), with 62 and 60 participants respectively.

Danaher Collaboration Aims to Enhance HER2 Testing Accuracy for Breast Cancer ADCs

A new, high-sensitivity HER2 assay developed by Dr. Rimm's lab aims to improve the accuracy and sensitivity of HER2 testing, crucial for identifying patients who may benefit from ADCs.
The assay utilizes immunofluorescence to measure HER2 antibody binding, offering a more quantitative approach compared to traditional methods, potentially increasing sensitivity by tenfold.

Taysha's TSHA-102 Gene Therapy Shows Promise in Rett Syndrome Trials

Taysha Gene Therapies is evaluating TSHA-102, an AAV-based gene therapy, in Phase 1/2 REVEAL trials for both adolescent/adult and pediatric patients with Rett syndrome.
TSHA-102 delivers a miniMECP2 gene via an AAV9 vector, utilizing the miRARE platform to regulate cellular expression of both endogenous and exogenous MECP2.

Egetis Therapeutics Files Patent for Tiratricol Production Process

Egetis Therapeutics has submitted a patent application to the USPTO for novel processes of preparation for tiratricol.
The new synthetic routes aim to enhance the efficiency of tiratricol production to meet growing demands.

Clinical Trials in Essential Thrombocythemia (ET)

PharmaEssentia is conducting clinical trials for Essential Thrombocythemia (ET), focusing on the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft compared with anagrelide as second-line therapy for adult patients resistant or intolerant to hydroxyurea.

FDA Approves Trofinetide for Rett Syndrome Treatment

The US Food and Drug Administration (FDA) has approved trofinetide, a synthetic analog of glycine-proline-glutamate (GPE), for the treatment of Rett syndrome (RTT) in adults and pediatric patients aged 2 years and older. This approval marks a significant milestone in the treatment of RTT, a rare neurodevelopmental disorder, following years of scientific and clinical research.

Ropeginterferon Alfa-2b Evaluated as Second-Line Therapy for High-Risk Essential Thrombocythemia in SURPASS-ET Trial

The SURPASS-ET trial is evaluating ropeginterferon alfa-2b as a second-line treatment for high-risk essential thrombocythemia (ET).
This Phase III trial compares ropeginterferon alfa-2b to anagrelide in patients resistant to or intolerant of hydroxyurea.

Reference News

[1]
Egetis has decided to explore RTH-beta as the next indication for tiratricol (Emcitate®)
placera.se · Dec 4, 2024

Egetis Therapeutics selects Resistance to Thyroid Hormone beta (RTHβ) as next indication for tiratricol (Emcitate®), pla...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy